• Home
  • Study Details

FLOW - effect of semaglutide v placebo on renal impairment in individuals with type 2 diabetes and chronic kidney disease

Chronic kidney disease (CKD) and diabetes often co-exist and, for the majority of cases, the kidney damage and/or reduced kidney function is caused directly by longstanding and poorly controlled diabetes. Improved glycemic control has been suggested to reduce the progression of CKD in type 2 diabetes (T2D) and both glycemic and blood pressure control are key recommendations in international treatment guidelines for CKD in T2D. Yet there remains a major unmet medical need to improve the treatment of CKD in patients with T2D. The purpose of this trial is to demonstrate that semaglutide subcutaneously (s.c.) delays the progression of renal impairment and lowers the risk of renal and cardiovascular mortality in subjects with T2D and CKD.

Age & Gender

  • 18 years ~ 99 years
  • Male, Female


North Carolina (Statewide)

What will be asked of you

7-11 phone visits


$50 for in-person visits, $25 for phone visits

In-person visits : 17
Phone or online visits : 11
Total length of participation : 3-5 years

Looking for Specific Volunteers

Able to participate:

  • Diagnosed with type 2 diabetes; HbA1c < or = 10%
  • Renal impairment defined by laboratory values
  • Treatment with maximum labelled or maximum tolerated RAAS blocking agent, including an ACE inhibitor or ARB.

Not eligible if:

  • Are pregnant, breast-feeding, or intend to become pregnant
  • Use of a GLP-1 receptor agonist within 30 days prior to screening
  • Current chronic or intermittent hemodialysis or peritoneal dialysis
  • Combination use of an ACE inhibitor and ARB

Contact the Team

Visit Location

100% Remote (online, phone, text)

Additional Study Information

Principal Investigator

Marian Kirkman

Study Topics

Kidneys and Liver

IRB Number


logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research
Research for Me logo

Copyright © 2013-2020 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.


  • This email address is being protected from spambots. You need JavaScript enabled to view it.